Top Markets
Coin of the day
Frequency Therapeutics, Inc. Frequency Therapeutics, Inc.

Frequency Therapeutics, Inc.

FREQ
株式のランク #32262
Frequency Therapeutics, Inc. is a clinical-stage biotechnology company... Frequency Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing treatments that unlock the body's inherent capacity for regeneration to restore impaired functions. Their "Progenitor Cell Activation" approach leverages small molecules to stimulate progenitor cells within the body, encouraging the formation of new, functional tissues. The company's flagship product candidate, FX-322, is currently in Phase IIa clinical trials, aiming to address the fundamental cause of sensorineural hearing loss. Beyond this, Frequency is also advancing therapies for various degenerative diseases, including multiple sclerosis, and ailments impacting muscles, the gastrointestinal system, skin, and bones. For the development and commercialization of FX-322, the company holds a license and collaboration agreement with Astellas Pharma Inc. Additionally, it maintains collaboration and licensing agreements with esteemed organizations such as Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. Founded in 2014, Frequency Therapeutics, Inc. is headquartered in Lexington, Massachusetts.
株価
$0.2996
最終同期: 2023-11-03
時価総額
$10.58M
変化(1日)
5.94%
変化(1年)
0.00%
US
取引 Frequency Therapeutics, Inc. (FREQ)

カテゴリー

Frequency Therapeutics, Inc.(FREQ)の利益
2026 時点の利益 TTM: 0
Frequency Therapeutics, Inc. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Frequency Therapeutics, Inc. の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益